Washington Capital Management Inc. lessened its position in Solventum Corporation (NYSE:SOLV – Free Report) by 16.7% in the second quarter, HoldingsChannel reports. The fund owned 7,500 shares of the company’s stock after selling 1,500 shares during the quarter. Washington Capital Management Inc.’s holdings in Solventum were worth $569,000 as of its most recent SEC filing.
A number of other hedge funds have also recently added to or reduced their stakes in SOLV. Rossby Financial LCC acquired a new stake in Solventum in the first quarter valued at approximately $25,000. Strengthening Families & Communities LLC grew its stake in Solventum by 376.8% in the first quarter. Strengthening Families & Communities LLC now owns 329 shares of the company’s stock valued at $25,000 after acquiring an additional 260 shares during the period. Hara Capital LLC acquired a new stake in Solventum in the first quarter valued at approximately $38,000. Smartleaf Asset Management LLC grew its stake in Solventum by 193.4% in the first quarter. Smartleaf Asset Management LLC now owns 534 shares of the company’s stock valued at $40,000 after acquiring an additional 352 shares during the period. Finally, Costello Asset Management INC acquired a new stake in Solventum in the first quarter valued at approximately $42,000.
Analyst Ratings Changes
A number of equities research analysts have commented on the company. Morgan Stanley raised Solventum from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $80.00 to $103.00 in a research note on Tuesday, July 15th. Wells Fargo & Company raised their target price on Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a report on Monday, September 15th. Piper Sandler restated an “overweight” rating and issued a $94.00 target price (up previously from $87.00) on shares of Solventum in a report on Friday, August 8th. Jefferies Financial Group started coverage on Solventum in a report on Thursday, September 11th. They issued a “hold” rating and a $80.00 target price on the stock. Finally, Argus upgraded Solventum from a “hold” rating to a “buy” rating and set a $90.00 target price on the stock in a report on Tuesday, July 1st. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Solventum has a consensus rating of “Hold” and a consensus target price of $85.44.
Solventum Stock Performance
Shares of Solventum stock opened at $71.43 on Monday. The business’s fifty day simple moving average is $72.84 and its 200 day simple moving average is $72.23. The firm has a market capitalization of $12.39 billion, a P/E ratio of 33.07, a price-to-earnings-growth ratio of 2.90 and a beta of 0.53. Solventum Corporation has a 12 month low of $60.70 and a 12 month high of $85.92. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14.
Solventum (NYSE:SOLV – Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, topping analysts’ consensus estimates of $1.45 by $0.24. The business had revenue of $2.16 billion for the quarter, compared to analyst estimates of $2.12 billion. Solventum had a return on equity of 29.93% and a net margin of 4.52%.Solventum’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same period last year, the company posted $1.56 earnings per share. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. As a group, analysts anticipate that Solventum Corporation will post 6.58 EPS for the current year.
About Solventum
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
See Also
- Five stocks we like better than Solventum
- Top Biotech Stocks: Exploring Innovation Opportunities
- SoundHound Breaks Critical Resistance: How High Can It Get Now?
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Klarna IPO: BNPL Stock or Something Bigger?
- EV Stocks and How to Profit from Them
- Why Teradyne Is a Core Play in the AI Hardware Boom
Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV – Free Report).
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.